35 completed, 12 unknown, 4 recruiting, 2 terminated. 19 Not applicable, 12 Phase 2, 9 Phase 3, 5 Phase 1, 5 Phase 4.
Follow Meningitis, Cryptococcal: new trials by email Literature Review of Meningitis, Cryptococcal trials Research Report on Meningitis, Cryptococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole - Cryptococcal Antigenemia, HIV-1-infection | Phase 3 | Not yet recruiting | University of Minnesota | 505 | 2027-01-05 | 2026-09-03 |
| Platform Trial For Cryptococcal Meningitis (PLATFORM-CM) Standard of care, Oteseconazole - antifungal therapy 1, Turletricin injection - antifungal therapy 2 - Hiv, Cryptococcal Meningitis | Phase 2 / Phase 3 | Recruiting | David Boulware | 2000 | 2025-05-28 | 2026-07-27 |
| Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis AMBITION trial control, Flucytosine - Cryptococcal Meningitis | Phase 2 | Completed | University of Minnesota | 48 | 2024-04-09 | 2025-08-27 |
| Amphotericin B for Non-HIV Cryptococcal Meningitis Patients Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks., Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks. - Cryptococcal Meningitis, Antifungal Agents | Phase 4 | Unknown | Huashan Hospital | 250 | 2023-08-13 | 2023-12-21 |
| Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City Histoplasma Urine Antigen Lateral Flow Antigen test, Cryptococcal Lateral Flow Antigen test, Tuberculosis-lipoarabinomannan Lateral Flow Antigen test - Acquired Immunodeficiency Syndrome, Histoplasmosis AIDS | Not applicable | Unknown | National Institute of Respiratory Diseases, Mexico | 211 | 2023-04-01 | 2023-01-17 |
| Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 MAT2203, Amphotericin B - Cryptococcal Meningitis | Phase 3 | Unknown | Matinas BioPharma Nanotechnologies, Inc. | 270 | 2023-01-01 | 2022-09-15 |
| Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis Amphotericin B Colloidal Dispersion, flucytosine, fluconazole - Cryptococcal Meningitis | Not applicable | Unknown | Peking Union Medical College Hospital | 30 | 2022-08-22 | 2022-07-22 |
| Three Induction Treatments on Cryptococcal Meningitis Voriconazole 200mg, amphotericin B deoxycholate (0.4-0.5mg/kg/d), Amphotericin B-deoxycholate (0.7-1.0mg/kg/d) - Cryptococcal Meningitis, HIV/AIDS | Early Phase 1 | Unknown | First Affiliated Hospital of Zhejiang University | 120 | 2021-01-25 | 2021-02-02 |
| Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week - Cryptococcal Meningitis | Completed | University of Pharmacy, Yangon | 30 | 2020-10-01 | 2022-04-21 | |
| The Lived Experience of Participants in an African Randomised Trial In-depth interviews - HIV, Cryptococcal Meningitis | Completed | London School of Hygiene and Tropical Medicine | 89 | 2020-02-05 | 2022-04-06 | |
| AmB Dose for Cryptococcal Meningitis Amphotericin B, Flucytosine - Cryptococcal Meningitis, HIV Infections | Phase 3 | Unknown | Shanghai Public Health Clinical Center | 40 | 2020-01-02 | 2019-10-29 |
| Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) MAT2203, Amphotericin B - Cryptococcal Meningitis | Phase 1 / Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 178 | 2019-10-24 | 2023-03-31 |
| Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia Single dose liposomal Amphotericin and Fluconazole, Fluconazole - Cryptococcal Meningitis | Phase 2 / Phase 3 | Recruiting | Makerere University | 356 | 2019-06-20 | 2026-04-28 |
| Treatment With Tamoxifen in Cryptococcal Meningitis Tamoxifen, Amphotericin B, Fluconazole - Meningitis Streptococcal, Hiv | Phase 2 | Completed | Oxford University Clinical Research Unit, Vietnam | 50 | 2017-10-10 | 2019-12-02 |
| Driving Reduced AIDS-associated Meningo-encephalitis Mortality DREAMM - AIDS-Related Opportunistic Infections, Meningo-encephalitis | Not applicable | Completed | St George's, University of London | 495 | 2016-04-23 | 2022-05-04 |
| Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Liposomal amphotericin B - Cryptococcal Meningitis | Phase 4 | Unknown | Hui Bu | 40 | 2016-01-01 | 2016-02-22 |
| Vietnam Cryptococcal Retention in Care Study - Version 2.1 Preemptive high-dose Fluconazole - HIV/AIDS, Cryptococcal Meningitis | Unknown | National Hospital for Tropical Diseases, Hanoi, Vietnam | 1184 | 2015-08-14 | 2017-09-12 | |
| Vietnam Cryptococcal Retention in Care Study Version 1.0 Fluconazole - Meningitis, Cryptococcal, Central Nervous System Fungal Infections | Unknown | National Hospital for Tropical Diseases, Hanoi, Vietnam | 2612 | 2015-08-14 | 2017-09-13 | |
| Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS Fluconazole, Antiretroviral therapy - Cryptococcal Meningitis | Not applicable | Unknown | ANRS, Emerging Infectious Diseases | 186 | 2015-07-01 | 2018-03-15 |
| Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report Vietnam Cryptococcal Retention in Care Study (CRICS) - Cryptococcal Meningitis | Phase 1 | Completed | National Hospital for Tropical Diseases, Hanoi, Vietnam | 1177 | 2015-06-01 | 2018-03-29 |
Showing 20 of 54. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (27) · HIV Infections (25) · Cryptococcosis (21) · Meningitis (21) · AIDS-Related Opportunistic Infections (17) · Brain Diseases (2) · Meningitis, Bacterial (2) · Meningitis, Fungal (2) · Autoimmune Diseases (1) · Bacterial Infections (1) · Central Nervous System Fungal Infections (1) · Central Nervous System Infections (1) · Immunologic Deficiency Syndromes (1) · Latent Tuberculosis (1)
Bacterial Infections and Mycoses (54) · Central Nervous System Diseases (54) · Infections (54) · Neuroinflammatory Diseases (54) · Central Nervous System Fungal Infections (53) · Central Nervous System Infections (53) · Mycoses (53) · Nervous System Diseases (53) · Meningitis, Fungal (52) · Immune System Diseases (36) · Virus Diseases (36) · Blood-Borne Infections (35) · Communicable Diseases (35) · Immunologic Deficiency Syndromes (35) · Lentivirus Infections (35)
Fluconazole (27) · Amphotericin B (23) · Flucytosine (13) · liposomal amphotericin B (4) · amphotericin B, deoxycholate drug combination (3) · Antiretroviral Therapy, Highly Active (2) · Itraconazole (2) · Lamivudine (2) · Stavudine (2) · efungumab (2) · Dexamethasone (1) · Injections (1) · Nevirapine (1) · Nucleosides (1) · RMP 7 (1)
Pfizer (11) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · University of Minnesota (5) · National Hospital for Tropical Diseases, Hanoi, Vietnam (3) · ANRS, Emerging Infectious Diseases (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · Novartis Pharmaceuticals (2) · University of Zimbabwe (2) · Alkermes, Inc. (1) · Botswana-UPenn Partnership (1) · David Boulware (1) · First Affiliated Hospital of Zhejiang University (1) · Huashan Hospital (1) · Hui Bu (1) · Institute of Tropical Medicine, Belgium (1)
United States (23) · Uganda (10) · China (4) · Vietnam (4) · Zimbabwe (4) · Canada (3) · South Africa (3) · Thailand (3) · Botswana (2) · Cameroon (2) · Peru (2) · Burma (1) · Burundi (1) · Côte d’Ivoire (1) · Democratic Republic of the Congo (1)
Armstrong D (2) · David R Boulware, MD, MPH (2) · Radha Rajasingham, MD (2) · Angela Loyse, MD (1) · Azure T Makadzange, MD DPhil (1) · Azure T Makadzange, MD, DPhil (1) · Charles Kouanfack, MD, PhD (1) · Chiratidzo E Ndhlovu, MBBS, MSc (1) · Chiratidzo E Ndhlovu, MBChB, FRCP (1) · David B Meya (1) · David B Meya, MBCHB MMed (1) · David B Meya, MBChB (1) · David B Meya, MBChB, MMed, PhD (1)
PMID 39972326, PMID 30325463, PMID 32843994, PMID 19441980, PMID 19897055, PMID 20415574, PMID 23362285, PMID 24963568, PMID 26768369, PMID 30256903, PMID 30345376, PMID 30399034, PMID 30801037, PMID 31242860, PMID 31319498, PMID 31345462, PMID 31504335, PMID 32634122, PMID 32747357, PMID 33677986, PMID 33820784, PMID 34398238, PMID 34446679, PMID 34581270, PMID 35924841, PMID 36303432, PMID 36780493, PMID 36924288, PMID 37133586, PMID 37606364, PMID 37802567, PMID 38152404, PMID 38943665, PMID 39044381, PMID 40665233, PMID 40795226
R01NS086312 (1), U01AI089244 (1), U01GH000517 (1)